Below is the preliminary schedule of AETC Program sessions and poster presentations planned for the 2020 National Ryan White Conference on HIV Care & Treatment. The AETC National Coordinating Resource Center will also be exhibiting its collection of AETC Program training materials and clinical resources. This page will be updated as information becomes available; check back soon for the complete schedule.
The US Centers for Disease Control and Prevention issued updated interim infection prevention and control guidance for dental settings during the COVID-19 response on May 19, 2020, very similar to science-based guidance issued earlier in May by the American Dental Association (ADA).
I never thought my experience as a Black woman, nor my experience as a woman who enjoys sex, would combine in a way that could put me in jail. When I was diagnosed with HIV in 2003, I had a very limited understanding of what that meant with respect to accessing treatment, being virally suppressed, dating, disclosure, fear... living. I would wait until my family finished eating, washing clothes and dishes for the day before I would wash and clean for myself. This is no way to live while managing an illness.
From our colleagues at TargetHIV, Creative Responses to COVID-19 highlights some of the approaches Ryan White HIV/AIDS Program grantees are taking to respond to clinic changes and provider and patient needs during this unprecedented time of COVID-19. The blog post underlines three programmatic areas - policies and procedures, communication, and helping to fill basic needs like food and rent.
Web developers and digital content creators know that website accessibility and 508 compliance is a critical requirement. Their websites and web materials must meet all the accessibility laws and regulations. To ensure equal access to information for all, including those with disabilities. Because the RWHAP AETCs facilitate the transfer of high-quality clinical HIV information to healthcare professionals, it is essential that content is developed with accessibility laws and standards in mind.
A network of federally funded training centers has existed since the early 1990’s to educate and build the capacity of clinicians and healthcare professionals to diagnose, treat and manage HIV and other sexually transmitted diseases (STDs), substance use disorders (SUDs), mental health disorders and other social determinants of health, which impact access to quality care for vulnerable populations.
Hepatitis C virus (HCV) co-infection affects roughly 25% of people with HIV in the United States (U.S.).[i] To effectively combat this epidemic, ongoing provider education has been identified as a key initiative to enhance screening, diagnosis, linkage to care, and treatment of HCV.
At CROI 2019, investigators presented 48-week results from the Phase 3 international multisite ATLAS and FLAIR studies of long-acting 2-drug injectable therapy. The study regimen consisted of the integrase inhibitor cabotegravir (CAB) plus the NNRTI rilpivirine (RPV), both given every 4 weeks as intramuscular (IM) injections.
TDF/FTC (Truvada) is the only ARV combination currently approved by the FDA for use as preexposure prophylaxis (PrEP). The multinational Phase 3 DISCOVER Study compared the efficacy and safety of TAF/FTC (Descovy) with TDF/FTC, in HIV-uninfected cisgender MSM and transgender women at high risk of sexually acquired HIV.